These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 18498916)
61. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281 [TBL] [Abstract][Full Text] [Related]
62. Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects. Almeida S; Filipe A; Neves R; Spínola AC; Tanguay M; Ortuño J; Farré A; Torns A Clin Ther; 2010 Mar; 32(3):556-74. PubMed ID: 20399993 [TBL] [Abstract][Full Text] [Related]
63. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804 [TBL] [Abstract][Full Text] [Related]
64. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation. Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821 [TBL] [Abstract][Full Text] [Related]
65. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683 [TBL] [Abstract][Full Text] [Related]
66. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Pillans PI; Rigby RJ; Kubler P; Willis C; Salm P; Tett SE; Taylor PJ Clin Biochem; 2001 Feb; 34(1):77-81. PubMed ID: 11239520 [TBL] [Abstract][Full Text] [Related]
67. Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. Wigger M; Armstrong VW; Shipkova M; Wacke R; Nizze H; Streit F; von Ahsen N; Muscheites J; Glasenapp S; Stolpe HJ; Oellerich M Ther Drug Monit; 2002 Jun; 24(3):438-43. PubMed ID: 12021639 [TBL] [Abstract][Full Text] [Related]
73. Validation of limited sampling strategy for estimation of mycophenolic acid exposure during the first year after heart transplantation. Baraldo M; Cojutti PG; Isola M; Feruglio MT; Tursi V; Livi U; Furlanut M Transplant Proc; 2009 Dec; 41(10):4277-84. PubMed ID: 20005384 [TBL] [Abstract][Full Text] [Related]
74. [Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients]. Kuriata-Kordek M; Boratyńska M; Urbaniak J; Woźniak M; Patrzałek D; Szyber P; Klinger M Pol Merkur Lekarski; 2006 Aug; 21(122):161-3; discussion 164. PubMed ID: 17144102 [TBL] [Abstract][Full Text] [Related]
75. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Gaston RS; Kaplan B; Shah T; Cibrik D; Shaw LM; Angelis M; Mulgaonkar S; Meier-Kriesche HU; Patel D; Bloom RD Am J Transplant; 2009 Jul; 9(7):1607-19. PubMed ID: 19459794 [TBL] [Abstract][Full Text] [Related]
76. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis. Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293 [TBL] [Abstract][Full Text] [Related]
77. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
78. Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. Filler G; Lampe D; Mai I; Strehlau J; Ehrich JH Transpl Int; 1998; 11 Suppl 1():S82-5. PubMed ID: 9664950 [TBL] [Abstract][Full Text] [Related]
79. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772 [TBL] [Abstract][Full Text] [Related]
80. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]